Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma

Cancer ◽  
2006 ◽  
Vol 106 (11) ◽  
pp. 2327-2336 ◽  
Author(s):  
Emer O. Hanrahan ◽  
Kristine Broglio ◽  
Deborah Frye ◽  
Aman U. Buzdar ◽  
Richard L. Theriault ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Breast Carcinoma ◽  
Randomized Trial ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Primary Breast Carcinoma ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Cell Support

scholarly journals Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry

2014 ◽  
Vol 20 (4) ◽  
pp. 501-506 ◽  
Author(s):  
Paolo Pedrazzoli ◽  
Giovanni Martinelli ◽  
Alessandro Massimo Gianni ◽  
Gian Antonio Da Prada ◽  
Alberto Ballestrero ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
High Risk ◽  
Primary Breast Cancer ◽  
High Dose Chemotherapy ◽  
National Registry ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Cell Support

scholarly journals High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults

2006 ◽  
Vol 17 (10) ◽  
pp. 1479-1488 ◽  
Author(s):  
P. Pedrazzoli ◽  
J.A. Ledermann ◽  
J.-P. Lotz ◽  
S. Leyvraz ◽  
M. Aglietta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Solid Tumors ◽  
Hematopoietic Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Cell Support

High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma

Cancer ◽  
2001 ◽  
Vol 92 (10) ◽  
pp. 2508-2516 ◽  
Author(s):  
Jose Luis P�rez-Gracia ◽  
Ramon Colomer ◽  
Emilio Esteban ◽  
Ram�n Barcel� ◽  
Manuel Benavides ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Breast Carcinoma ◽  
Advanced Breast ◽  
High Dose ◽  
Stem Cell Support ◽  
Cell Support

High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial

2004 ◽  
Vol 22 (12) ◽  
pp. 2273-2283 ◽  
Author(s):  
A.R. Zander ◽  
N. Kröger ◽  
C. Schmoor ◽  
W. Krüger ◽  
V. Möbus ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Standard Dose ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Event Free Survival ◽  
Hematopoietic Stem ◽  
Free Survival ◽  
Stem Cell Support ◽  
Cell Support

Purpose Investigation of high-dose chemotherapy (HD-CT) followed by autologous hematopoietic stem-cell support compared with standard-dose chemotherapy (SD-CT) as adjuvant treatment in patients with primary breast cancer and 10 or more positive axillary lymph nodes. Patients and Methods Between November 1993 and September 2000, 307 patients were randomized to receive (following four cycles of epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2, intravenously every 21 days) either HD-CT of cyclophosphamide 1,500 mg/m2, thiotepa 150 mg/m2, and mitoxantrone 10 mg/m2, intravenously for 4 consecutive days followed by stem-cell support; or SD-CT in three cycles of cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2 intravenously on days 1 and 8, every 28 days. The primary end point was event-free survival. Results After a median follow-up of 3.8 years, 144 events with respect to event-free survival have been observed (HD-CT: 63 events; SD-CT: 81 events). The first event of failure (HD-CT v SD-CT) was an isolated locoregional recurrence (nine v 11), a distant failure (52 v 68), and death without recurrence (two v two). The estimated relative risk of HD-CT versus SD-CT was 0.75 (95% CI, 0.54 to 1.06; P = .095). Overall survival showed no difference (HD-CT: 40 deaths; SD-CT: 49 deaths). Conclusion There was a trend in favor of HD-CT with respect to event-free survival, but without statistical significance. Further follow-up and a meta-analysis of all randomized studies will reveal the effect of HD-CT as compared with SD-CT as adjuvant treatment in high-risk primary breast cancer.

Sign in / Sign up

Export Citation Format

Share Document